EMA accepts GSK's application to expand Nucala use
24th Mar 2025 07:28
(Sharecast News) - GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of 'Nucala', or mepolizumab, to include patients with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype.
Read moreFDA to review GSK's depemokimab
3rd Mar 2025 09:27
(Sharecast News) - Pharmaceutical giant GSK said on Monday that the US Food and Drug Administration has agreed to review its Biologics License Application for the use of its depemokimab asset in two indications.
Read moreLondon close: Stocks little changed after UK data dump
21st Feb 2025 15:46
(Sharecast News) - London stocks closed with little direction on Friday as investors weighed fresh economic data, including signs of slowing private sector growth.
Read moreGSK seen as potential target for activist investors
21st Feb 2025 11:54
(Sharecast News) - Drugmaker GSK has been tapped as a potential target for activist investors, according to Bloomberg, which noted that shares had fallen roughly 19% since spinning off its consumer health business in 2022.
Read moreLondon close: Stocks slip as US jobless claims rise
20th Feb 2025 16:06
(Sharecast News) - London equities ended lower on Thursday as investors reacted to a higher-than-expected rise in US jobless claims and a decline in UK consumer confidence.
Read moreGSK 5-in1 meningitis drug gets US approval
17th Feb 2025 07:04
(Sharecast News) - GSK said the US Food and Drug Administration has approved its Penmenvy drug to treat meningitis for use in individuals aged10 - 25 years.
Read moreGSK ups five-year sales outlook, but 2024 results come up short
5th Feb 2025 07:19
(Sharecast News) - GSK's annual revenues were held back weak vaccines sales, but shares in the pharma giant jumped on Wednesday after the company unveiled plans to buy back £2bn of stock over the next 18 months and raised its guidance for long-term growth.
Read moreGSK's pre-filled shingles vaccine accepted for review by EMA
27th Jan 2025 07:08
(Sharecast News) - GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the European Medicines Agency.
Read moreEU regulators expand usage of GSK's Jemperli cancer drug
20th Jan 2025 07:22
(Sharecast News) - European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced on Monday.
Read morePfizer pares back Haleon stake in £2.5bn sale
15th Jan 2025 08:10
(Sharecast News) - Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares in a £2.5bn sale.
Read moreLondon close: Stocks fall, pound weakens further on rising bond yields
13th Jan 2025 15:19
(Sharecast News) - London stocks ended Monday in negative territory, pressured by rising bond yields and diminished expectations for near-term interest rate cuts.
Read moreGSK to buy IDRx for up to $1.15bn
13th Jan 2025 07:04
(Sharecast News) - GSK on Monday said it was buying US-based biopharmaceutical company IDRx for up to $1.15bn.
Read moreGSK application for new Shingrix formulation accepted by FDA
10th Jan 2025 07:23
(Sharecast News) - GSK announced on Friday that the US Food and Drug Administration (FDA) has accepted its regulatory application for a prefilled syringe version of Shingrix, its recombinant zoster vaccine for preventing shingles.
Read moreGSK cancer drug candidate gets another breakthrough designation
7th Jan 2025 07:22
(Sharecast News) - GSK announced on Tuesday that its investigational antibody-drug conjugate GSK'227 has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for treating relapsed or refractory osteosarcoma in patients who had progressed after at least two prior lines of therapy.
Read moreLondon close: Stocks finish first week of 2025 weaker
3rd Jan 2025 17:12
(Sharecast News) - London stock markets closed in the red on Friday as sharp declines in airline, mining, and housebuilding stocks weighed on indices, with a lack of significant news and profit-taking following a recent rally dampening sentiment.
Read more